No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
LXRX Lexicon Pharmaceuticals
- 0.715
- -0.009-1.23%
Close Dec 20 16:00 ET
- 0.642
- -0.073-10.17%
Post 20:01 ET
258.36MMarket Cap-0.97P/E (TTM)
0.760High0.701Low7.37MVolume0.730Open0.724Pre Close5.31MTurnover4.04%Turnover RatioLossP/E (Static)361.49MShares3.73052wk High1.45P/B130.22MFloat Cap0.62052wk Low--Dividend TTM182.20MShs Float344.750Historical High--Div YieldTTM8.17%Amplitude0.620Historical Low0.720Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Stocks to Watch: Rumble, Lexicon Pharmaceuticals
FDA Rejects Lexicon's Zynquista for Diabetes, Kidney Disease
Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours
Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...
Express News | Lexicon Pharmaceuticals Inc - to Discontinue Zynquista Launch Preparations
Express News | Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (Sotagliflozin)
Heat List
US
Overall
Symbol
Price
% Chg
No Data